164 related articles for article (PubMed ID: 32839218)
21. Omadacycline: A Modernized Tetracycline.
Gallagher JC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S1-S5. PubMed ID: 31367739
[TBL] [Abstract][Full Text] [Related]
22. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
Tanaka SK; Steenbergen J; Villano S
Bioorg Med Chem; 2016 Dec; 24(24):6409-6419. PubMed ID: 27469981
[TBL] [Abstract][Full Text] [Related]
23. Omadacycline for Acute Bacterial Skin and Skin Structure Infections.
Abrahamian FM; Sakoulas G; Tzanis E; Manley A; Steenbergen J; Das AF; Eckburg PB; McGovern PC
Clin Infect Dis; 2019 Aug; 69(Suppl 1):S23-S32. PubMed ID: 31367742
[TBL] [Abstract][Full Text] [Related]
24. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
Lodise TP; Mistry R; Young K; LaPensee K
Clin Drug Investig; 2021 Mar; 41(3):269-275. PubMed ID: 33604769
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: Subanalysis from a randomized controlled trial.
Pai MP; Wilcox M; Chitra S; McGovern P
Respir Med; 2021 Aug; 184():106442. PubMed ID: 34058682
[TBL] [Abstract][Full Text] [Related]
26. Omadacycline: a therapeutic review of use in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Chopra T; Sandhu A; Theriault N; Meehan J; Tillotson G
Future Microbiol; 2020 Sep; 15():1319-1333. PubMed ID: 32959689
[TBL] [Abstract][Full Text] [Related]
27. Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic Models.
Lodise T; LaPensee K
Am Health Drug Benefits; 2019; 12(4):168-176. PubMed ID: 31428234
[TBL] [Abstract][Full Text] [Related]
28. Effect of Food on the Bioavailability of Omadacycline in Healthy Participants.
Tzanis E; Manley A; Villano S; Tanaka SK; Bai S; Loh E
J Clin Pharmacol; 2017 Mar; 57(3):321-327. PubMed ID: 27539539
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data.
Lakota EA; Van Wart SA; Trang M; Tzanis E; Bhavnani SM; Safir MC; Friedrich L; Steenbergen JN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32340986
[TBL] [Abstract][Full Text] [Related]
30. Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
Vacalis S; Brunton S; Gindi J
J Fam Pract; 2022 Jun; 71(5 Suppl):S10-S21. PubMed ID: 35776862
[TBL] [Abstract][Full Text] [Related]
31. Return of the tetracyclines: omadacycline, a novel aminomethylcycline antimicrobial.
Cho JC; Childs-Kean LM; Zmarlicka MT; Crotty MP
Drugs Today (Barc); 2018 Mar; 54(3):209-217. PubMed ID: 29771255
[TBL] [Abstract][Full Text] [Related]
32. Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Lodise T
Am Health Drug Benefits; 2018 Dec; 11(9):449-459. PubMed ID: 30746017
[TBL] [Abstract][Full Text] [Related]
33. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
O'Riordan W; Green S; Overcash JS; Puljiz I; Metallidis S; Gardovskis J; Garrity-Ryan L; Das AF; Tzanis E; Eckburg PB; Manley A; Villano SA; Steenbergen JN; Loh E
N Engl J Med; 2019 Feb; 380(6):528-538. PubMed ID: 30726689
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin structure infections.
Lodise TP; Gunter K; Mu F; Gao E; Yang D; Yim E; Sandor S; Berman G
J Manag Care Spec Pharm; 2023 Aug; 29(8):952-964. PubMed ID: 37307087
[No Abstract] [Full Text] [Related]
35. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
36. Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects.
Darpo B; Xue H; Tanaka SK; Tzanis E
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405867
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of 14C-Omadacycline in Rats.
Lin W; Flarakos J; Du Y; Hu W; He H; Mangold J; Tanaka SK; Villano S
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821446
[TBL] [Abstract][Full Text] [Related]
38. Omadacycline Enters the Ring: A New Antimicrobial Contender.
Barber KE; Bell AM; Wingler MJB; Wagner JL; Stover KR
Pharmacotherapy; 2018 Dec; 38(12):1194-1204. PubMed ID: 30290000
[TBL] [Abstract][Full Text] [Related]
39. Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Mistry R; Lodise T
Am Health Drug Benefits; 2019 Feb; 12(1-Supplement 2):S13-S24. PubMed ID: 30996767
[TBL] [Abstract][Full Text] [Related]
40. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections.
Villano S; Steenbergen J; Loh E
Future Microbiol; 2016 Oct; 11():1421-1434. PubMed ID: 27539442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
